As of June 21, 2025, Sienna Biopharmaceuticals Inc (SNNAQ) reports a ROE (Return on Equity) of -276.40%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Sienna Biopharmaceuticals Inc's ROE (Return on Equity)
Over recent years, Sienna Biopharmaceuticals Inc's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2018-12-31 | -276.40% |
| 2017-12-31 | -55.42% |
| 2016-12-31 | -95.68% |
| 2015-12-31 | -278.80% |
This slight upward trend highlights how Sienna Biopharmaceuticals Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Sienna Biopharmaceuticals Inc's ROE (Return on Equity) to Peers
To better understand Sienna Biopharmaceuticals Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Sienna Biopharmaceuticals Inc (SNNAQ) | -276.40% |
| Medican Enterprises Inc (MDCN) | 680.75% |
| Spotlight Innovation Inc (STLT) | 396.49% |
| Quanta Inc (QNTA) | 386.33% |
| Cannabis Global, Inc. (CBGL) | 354.30% |
| AtheroNova Inc (AHROQ) | 312.21% |
Compared to its competitors, Sienna Biopharmaceuticals Inc's ROE (Return on Equity) is among the lowest compared to peers, which may indicate less effective deployment of shareholders' capital.